Consortium advances a test to detect drug-induced liver injury

Researchers from Critical Path Institute’s (C-Path) Predictive Safety Testing Consortium have proposed glutamate dehydrogenase (GLDH) as a more liver-specific biomarker for detecting liver injury, supporting clearer decision-making. Currently, alanine aminotransferase and aspartate aminotransferase (ALT and AST) are considered the “gold standard” biomarkers in clinical practice and drug development.